Cartherics and Catalent Expand Commercial License Agreement

Cartherics Pty Ltd, a biotechnology company developing off‑the‑shelf immune cell therapies for high‑impact women’s diseases, including ovarian cancer and endometriosis, and Catalent, Inc., the leader ...
Seeking Alpha

Orion and Invenra announce discovery service and commercial license agreement to develop innovative bispecific antibody cancer therapeutics

Orion Corporation (“Orion”) and Invenra Inc. (“Invenra”), an innovative biotechnology company with proprietary technologies for discovering novel therapeutics, today announced that they have entered ...
USA Today

OBI Pharma and TegMine Therapeutics Sign Exclusive Global License Agreement for Glycan-Targeting ADC

TAIPEI, TW / ACCESS Newswire / January 12, 2026 / OBI Pharma (4174.TWO) announced that it has entered into a commercial license agreement with TegMine Therapeutics, Inc. (TegMine), a San ...
Morningstar

Eisai and Henlius Enter into Exclusive Commercial License Agreement for Anti-PD-1 Antibody Serplulimab in Japan

TOKYO and SHANGHAI, Feb. 5, 2026 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Shanghai Henlius Biotech, Inc. (Headquarters ...